anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cancer is a leading cause of mortality in humans, but the efficacy of current treatments for many cancers is limited, as they lack unique mechanistically defined targets. Here, we show that, upon malignant transformation, aggressive oncocells generate a second membrane exterior to their plasma membrane to form cytocapsulas (CCs) and cytocapsular tubes (CCTs), which all together constitute cytocapsular oncocells with pleotropic biological functions in cancer patient tissues in vivo. Proteomic and biochemical analyses revealed that the PMCA2 calcium pump is highly up-regulated in CCs and CCTs in malignant tumors but not in normal tissues, thus identifying a unique cancer biomarker and target for cancer therapy. Cytocapsular oncocells are universally present in solid cancers and appear in hematologic cancers in immune organs. Multi-cell malignant tumors are also enveloped by protective CC membranes. These cytocapsular tumors (CTs) generate numerous CCTs that form freeways for cancer cell metastasis to both neighboring and distant destinations. Entire cytocapsular tumor networks (CTNs) dominate physical cancer metastasis pathways in cancer patients in vivo. Later, CCTs invade micro blood vessels and release cytocapsular oncocells into the blood, providing a source of circulating tumor cells. CTNs interconnect cytocapsular tumors in primary and secondary cancer niches, creating larger cytocapsular tumor network systems (CTNSs). Primary and secondary CTNSs are in turn interconnected, forming dynamic and integrated CTNSs. Thus, interconnected cytocapsular oncocells, CTNs, and CTNSs coordinate cancer progression via the integrated cytocapsular membrane systems.
Cochlear implantation (CI) is the primary intervention for patients with sensorineural hearing loss to restore their hearing. However, approximately 90 % of CI recipients experience unexpected fibrosis around the inserted electrode arrays due to acute and chronic inflammation. This fibrosis leads to progressive residual hearing loss. Addressing this complication is crucial for enhancing CI outcomes, yet an effective treatment has not yet been found. In this study, we developed a multifunctional dexamethasone (DXM)-loaded polytrimethylene carbonate (PTMC) electrode coating to mitigate inflammatory reactions and fibrosis after CI. This thin and flexible coating could preserve the mechanical performance of the electrode and reduce the implantation resistance for CI. The in vitro release studies demonstrated the DXM-PTMC coating's efficient drug loading and sustained release capability over 90 days. DXM-PTMC also showed long-term stability, high biocompatibility, and effective anti-inflammatory effects in vitro and in vivo. Compared with the uncoated group, DXM-PTMC coating significantly inhibited the expression of inflammatory factors, such as NO, TNF-α, IL-1β, and IL-6. DXM-PTMC coating suppressed fibrosis in rat implantation models for 3 weeks by reducing both acute and chronic inflammation. Our findings suggest that DXM-PTMC coating is a novel strategy to improve the outcomes of CI.
PURPOSE: To provide a treatment of a cardiovascular disease and more specifically, an atherosclerosis. CONSTITUTION: The method for treatment of the atherosclerosis. This method includes medication of a patient having the atherosclerosis with a non-cysteine, non-thiolic product for stimulating intracellular glutathione biosynthesis. In a more specific example the non-cysteine, the non-thiolic product is L-2- oxothiazolidine-4-carboxylate. The method for preventing the atherosclerosis lesion of the patient having the danger of the atherosclerosis. Further, the method for prophylaxis of the reconstriction of the Patient receiving an invasive procedure for the purpose of treating the atherosclerosis.
Obstructive Sleep Apnea as confirmed by full-night attended in-lab polysomnography showing an apnea-hypopnea index of \>=15 per hour or, alternatively, an apnea-hypopnea index \>=5 with excessive daytime sleepiness as defined by an Epworth Sleepiness Scale score \>9. Furthermore, co-existing hypoventilation during sleep, defined by the presence of intermittent hypercapnia as measured by transcutaneous capnometry and arterialized capillary blood gas analysis.
This study is evaluating a new technique for performing Thalamotomy for tremor control. While current techniques have possible invasive or radiation effects, the use of ExAblate if totally non-invasive and without any radiation. After informed consent and screening, eligible subjects will be randomized to either an ExAblate treatment or an ExAblate Sham or "fake" procedure. The chance of randomization to Sham is one out of four. Subjects who are randomized to Sham Control will undergo the same procedure and follow-up visits through their Month 3 visit. After the Month 3 assessments are complete, all subjects will be unblinded and those in the Sham treated group will have the option for an actual ExAblate treatment in an unblinded fashion, as long as they still qualify for ExAblate treatment. All subjects will be followed at 6 and 12 months and for up to 5 years as directed by their doctor.
OBJECTIVE: To determine the prevalence of celiac disease and its predictors in children with constipation.
METHODS: A hospital-based cross-sectional comparative study was conducted between November, 2018 to April, 2020. Children aged 1-12 years were screened for the presence of constipation as per ROME IV criteria and designated as cases. Age and sex matched healthy children with normal bowel habits were enrolled as comparison group. Participants underwent a detailed history and examination, and were screened for celiac disease by estimating serum anti-tissue transglutaminase IgA antibody levels (tTG-IgA). Upper gastrointestinal endoscopy and duodenal biopsy were performed in all participants who tested positive on screening (serum tTG-IgA ≥ 20 U/mL). The prevalence of celiac disease and associated factors were compared between the two groups.
RESULTS: A total of 460 children (230 in each group) with mean (SD) age 64.08 (37.12) months were enrolled. Twenty-one (4.6%) children screened positive for anti tTG antibodies, among these 15 (75%) children had biopsy features suggestive of celiac disease (Marsh grade III). Children with constipation had significantly higher prevalence of celiac disease (5.65% vs 0.87%, P = 0.004) compared to children without constipation. Wasting and stunting were significantly associated with celiac disease in constipated children (P < 0.001).
CONCLUSION: Children with constipation and associated growth failure have a high prevalence of celiac disease.
The study will start for each subject in the clinic setting during a standard pre-operative office visit. Consent for the study will be obtained after explaining all aspects of the study. The subjects will be randomly separated into two groups. Half of the subjects will have their procedure performed under standard tourniquet pressure, and the other half of the subjects will have their procedure performed with a distal photoplenthysmography probe that will calculate Limb Occlusion Pressure and inflate the tourniquet to the calculated Limb Occlusion Pressure. The subject will undergo their scheduled procedure in the operating room. The subject will also keep a daily pain and opioid consumption diary at home for two weeks after the surgery. The subject will complete patient outcome questionnaires before the surgery, two weeks after the operation, and 8 weeks after the operation to assess patient outcomes. The subject can complete the questionnaires at home, but if they do not, they will have the option to fill the out during their clinic visits. The patient's pre and post OP questionaries' will be the indicators for patient outcomes. All of the standardized questionnaires give calculated scores based off the patients' responses. As the subject improves their score will increase.The research team can compare change in score between the two groups and change with in groups to access patient outcomes.

To maintain the double blind nature of the study, the tourniquet will be placed, inflated, and draped over before the surgeon enters the operating room. Someone else on the research team, one of the coordinators or one of the residents will record the patients' systolic blood pressure and cuff pressure of the tourniquet before the attending enters the OR. This way the surgeon is still blind to the cuff pressure technique used, LOP or STP, when they rate the quality of the bloodless field after the surgery using a VAS scale.

All of these documents are attached on the summary page under additional documents on the Psycho-Physiological Testing page under number 1. List all the measures/instruments that will be used for this study. The VAS pain and opioid consumption diary is titled LOP pain diary cover page and LOP pain diary. The questionnaires that will be used are DASH, IKDC Subject Knee Evaluation Form, KOOS Junior, KOOS Lysholm, Marx, Michigan Hand Outcomes, Patient Rated Wrist Evaluation, Promis Bank v 1.2 Physical Function, PROMIS SF v 1.1 Global Health, and Tegner Activity Level Scale.
The present invention relates to an activated carbon infusion solution, a preparation method thereof and an application thereof to prepare medicine for treating cancer. The activated carbon infusion solution comprises a pure activated carbon particulate injection solution for intravenous transfusion, an activating activated carbon particulate injection solution, a catalyst adsorption activated carbon injection solution and various medicine carrying activated carbon injection solutions. The activated carbon infusion solution is characterized in that the surface area of activated carbon as raw materials is not less than 400 to 10000 m or higher, the content of heavy metal is not more than 0.1 to 10 ppm, the content of other soluble metallic ions is not more than 0.1 to 10 ppm, the ash content is less than 2%, the total pore volume is more than 0.3 to 6cm. and the adsorptive value of 0.15% of methylene blue is more than 6 to 30. The particle diameter of activated carbon particulate in the activated carbon infusion solution is from 35 mum to 2 nm, the main particle size range is from 6 mum to 2 nm, wherein 3 mum to 2 nm of particulate occupies 99%, 6 mum to 3 mum of particulate is not more than 1%, the maximum diameter is from 35 mum to 6 mum, and the activated carbon particulate is not more than 2*10<4> per mg of activated carbon miropowder. After the activated carbon particulate is input in blood through venae, the consistency with tissues is excellent without toxic or side effect. The present invention has the advantages of no pessimal stimulation, no immunogenicity, safety and good curative effect and has superordinary curative effects on cancer, blood vessel atherosclerosis, coronary diseases, cerebral thrombosis, infectious diseases, azotemia, acute organic and inorganic poisoning, etc.
COPD is the fourth leading cause of death in the US, and COPD exacerbations result in approximately 700,000 hospitalizations annually. Patients who do not respond to pharmacotherapy are placed on invasive mechanical ventilation (IMV) or noninvasive mechanical ventilation (NIV). Although IMV reverses hypercapnia/hypoxia, it can cause significant morbidity and mortality. NIV is an alternative ventilatory option for acute respiratory failure that provides positive pressure ventilation via a mask. Multiple randomized controlled trials and analyses of real-world data have shown that patients treated with NIV are less likely to require IMV, and have lower mortality and length of hospital stay. NIV is recommended in COPD guidelines as the first-line treatment for patients with severe exacerbation who have failed pharmacologic treatment. Yet, despite compelling evidence of benefit, we have previously demonstrated substantial variation in the implementation of NIV across hospitals, leading to preventable morbidity and mortality.

Through a series of mixed-methods studies, we have found that successful implementation of NIV requires physicians, respiratory therapists (RTs), and nurses to communicate and collaborate effectively to select appropriate patients for treatment, and to carefully manage patients after NIV initiation. These studies suggest that efforts to increase the use of NIV in COPD need to account for the complex and interdisciplinary nature of NIV delivery and the need for team coordination. The main goal of this project is to determine the impact of interprofessional educational (IPE) strategies in 20 hospitals with low NIV use in COPD by conducting non-randomized open cohort step wedge trial. The IPE will target complex team-based care in NIV delivery. The primary outcome of the trial is change in the hospital rate of NIV use among patients with COPD requiring ventilatory support. The central hypothesis is that IPE will lead to improvement in the uptake of NIV, and that RT autonomy and team functionality will act as mediators. The goal will be accomplished by completing three specific aims. Aim 1 will compare the change in NIV use over time among patients with COPD in hospitals enrolled by comparing their NIV rates from before the IPE training, to after the training. Aim 2 will explore mediators' role (RT autonomy and team functionality) on the relationship between the implementation strategies and implementation effectiveness. In Aim 3, we will assess the acceptability and feasibility of the educational training through interviews with providers. This proposal is significant because NIV is the only therapy that has been shown to improve short-term survival for patients hospitalized for exacerbation of COPD, yet a large number of hospitals still have not adopted this approach fully.
SBP-101 is administered as a subcutaneous injection once daily, Monday through Friday for 3 weeks (total of 15 doses) followed by a 5-week rest period (3 weeks on, 5 weeks off = 1 treatment cycle). Dose escalation in phase 1a will continue until the maximum tolerated dose is determined.
Serious psychiatric adverse experiences have been reported in patients treated with efavirenz. In controlled trials of 1008 patients treated with regimens containing efavirenz for a mean of 2.1 years and 635 patients treated with control regimens for a mean of 1.5 years, the frequency (regardless of causality) of specific serious psychiatric events among patients who received efavirenz or control regimens, respectively, were severe depression (2.4%, 0.9%), suicidal ideation (0.7%, 0.3%), nonfatal suicide attempts (0.5%, 0), aggressive behavior (0.4%, 0.5%), paranoid reactions (0.4%, 0.3%), and manic reactions (0.2%, 0.3%). When psychiatric symptoms similar to those noted above were combined and evaluated as a group in a multifactorial analysis of data from Study 006, treatment with efavirenz was associated with an increase in the occurrence of these selected psychiatric symptoms. Other factors associated with an increase in the occurrence of these psychiatric symptoms were history of injection drug use, psychiatric history, and receipt of psychiatric medication at study entry; similar associations were observed in both the efavirenz and control treatment groups. In Study 006, onset of new serious psychiatric symptoms occurred throughout the study for both efavirenz-treated and control-treated patients. One percent of efavirenz -treated patients discontinued or interrupted treatment because of one or more of these selected psychiatric symptoms. There have also been occasional postmarketing reports of death by suicide, delusions, and psychosis-like behavior although a causal relationship to the use of efavirenz cannot be determined from these reports. Postmarketing cases of catatonia have also been reported and may be associated with increased efavirenz exposure. Patients with serious psychiatric adverse experiences should seek immediate medical evaluation to assess the possibility that the symptoms may be related to the use of efavirenz, and if so, to determine whether the risks of continued therapy outweigh the benefits [see Adverse Reactions (6.1)].
The EPIC Observational Study is a longitudinal, prospective, observational study that was originally conducted at 59 sites. The current five-year extension study is being conducted at 54 sites.

The EPIC Observational Study will serve as a freestanding epidemiologic study of the risk factors for and clinical impact of initial Pa acquisition and anti-pseudomonal therapy. Defining the risk factors for Pa acquisition can potentially allow for preventive measures and identification of high-risk populations requiring closer monitoring. Despite rigorous data collection, previous studies have been limited by small sample sizes and by conduct at one or two centers. This study will include a much larger sample size from many more centers than previous studies. It will thus provide for more generalizable results and more precise risk estimates for previously identified risk factors for Pa acquisition, and it will allow for exploration of novel risk factors not included in earlier studies. Better understanding of the clinical outcomes associated with Pa acquisition and the outcomes associated with different types of anti-pseudomonal therapies will inform the development of rational early intervention treatment regimens. Better knowledge about temporal relationships between respiratory signs and symptoms, Pa serology, and CF airway microbiology may lead to improved strategies for early detection of Pa and could have important implications for the timing of interventions aimed at preventing or treating early Pa acquisition. Finally, this study will serve as an important source of Pa and S. aureus isolates, serum samples, and DNA samples that will be used and banked for studies designed to enhance the understanding of the pathogenesis of CF, e.g., microarray investigations of early Pa isolates, investigations to identify proteomic biomarkers of airway inflammation, and investigations to identify genetic factors related to CF disease progression, including early lung disease, and clinical outcomes.
Participants received 10 mg/kg of ipilimumab administered intravenously once every 3 weeks for 4 doses (Induction Phase). Then, once every 12 weeks (Maintenance Phase), until disease progression or unacceptable toxicity occurs.
PURPOSE:The titled capsule, containing contents obtained by adding a phospholipid to liver oil, and capable of preventing the deterioration of films with time. CONSTITUTION:A capsule of liver oil obtained by adding >=0.05wt%, preferably 0.1-1.0wt%, based on liver oil, e.g. cod-liver oil or shark liver oil, phospholipid, e.g. phosphatidyl choline phosphatidyl inositol or phosphatidyl ethanolamine, thereto. A flavoring agent, e.g. peppermint oil, cinnamon oil or orange oil, a colorant, e.g. beta-carotene or natural chlorophyll, an oil-soluble vitamin, e.g. vitamin E or K, a vegetable oil, e.g. wheat embryo bud oil, safflower oil or sesame oil, may be incorporated therewith. A film material for the soft capsule of the liver oil is obtained by gelatinizing gelatin, a water-soluble polyhydric alcohol or a derivative thereof, e.g. glycerol or sorbitol. The solubility of the resultant film will not change even after the lapse of 50 days at 50 deg.C.
Bitter gourd (BG) (Momordica charantia) is a highly nutritive vegetable from the cucumber family. The objective is to assess the impact of 12-weeks of BG supplementation on blood glucose levels in subjects with impaired fasting glucose levels. In a previous trial (Bitter-Zoet NL70259.081.19) the short-term effects of BG (4 weeks) were studied, but no effect was observed. In the current trial a different BG cultivar is chosen, the intervention period is prolonged, the dosage per day is higher and study subjects with slightly higher fasting blood glucose levels will be included. The study is a parallel, double blind, controlled trial in which study participants will receive a 12-week intervention with 3.6 g/d dried bitter-gourd supplements or a reference intervention with 3.6 g/d dried cucumber supplements. Research subjects will come to the research facility for a test day on four occasions, with an interval of 4 weeks. The main study parameter is fasting levels of plasma glucose. Secondary outcome measures are glucose tolerance, HbA1c, insulin and HOMA-IR and HOMA-B levels.
A system for managing patients in a hospital by using an RFID card and a service providing method thereof are provided to detect the movement path of a patient by using an RFID card and to inform the unauthorized movement of a patient to a medical staff. A client terminal(300) includes the followings. An input unit(310) inputs the information for issuing a card or supports an inquiry service for a patient. A communication module(320) exchanges information with a server(400), and a non-contact wireless frequency identification card(100) is manufactured by including the personal information of a patient. A gate hub(200) detects a signal depending on entrance state of a patient, who carries an RFID card, when the patient moves, and includes plural gates(210,220,230) which transmit the detected signal to a server unit. A database(600) provides conditions necessary for executing a sever processor and stores and manages the provided conditions.
Reduction in muscle mass (sarcopenia) is well documented in patients with chronic liver disease (CLD)leading to increased morbidity, mortality and poor quality of life. An equilibrium is maintained between the synthesis and degradation of muscles to maintain the muscle mass. However, an imbalance between the synthesis and degradation leads to loss of muscle mass. Various factors like alteration in dietary intake, hyper-metabolism, changes in amino acid profile, decreased physical activity, endotoxemia, hyperammonemia, increased myostatin levels have been postulated in the pathogenesis of muscle loss in liver disease. Reduced dietary intake, altered amino acid profile, decreased physical activity down regulate the anabolic pathway while the others increase the catabolic pathway. Increased level of myostatin inhibits the mTOR signaling and increases catabolism. Various therapeutic strategies such as increased calorie and protein intake, branched chain amino acid (BCAA) supplementation, late evening snack (LES), increased physical activity are the well accepted therapies. Hormone therapy (testosterone/growth hormone) also has been tried to improve muscle mass and function, reduce muscle catabolism in patients with CLD, however these newer treatment modalities i.e. hormone replacement, immune-nutrition and anti-myostatin antibodies are not free from adverse side-effects. Branched chain amino acids, a group of three essential amino acids (leucine, isoleucine, valine) have been tried since years in the setting of chronic liver disease patients for the treatment of hepatic encephalopathy and improvement in nutritional status. However, the studies assessing the impact of nutrition and BCAA in CLD have not assessed the direct impact on the muscle per se. The nutritional status has been assessed using different subjective methods like mid arm muscle circumference, triceps skin fold, nitrogen balance. Nutritional management is the cornerstone of the overall management of patients with cirrhosis, wherein BCAA constitutes an important therapeutic modality in the realm of nutrition in liver disease.

In the present study all the eligible cirrhotic patients will be randomized to a control group (receiving the nutritional therapy as per the standard nutritional practices and guidelines) or the intervention group (receiving BCAA supplementation over and above the standard nutrition therapy as per the standard nutritional practices and guidelines). Branched chain amino acids (BCAA) have the potential to up-regulate the anabolic pathway of muscle synthesis leading to improvement in muscle mass. Muscle mass as assessed by DEXA, along with changes in muscle histology, markers of the pathways that regulate muscle growth, functional capacity, and quality of life will be assessed after 3 months of BCAA intervention.